Friday, January 18, 2019

Encouraging Breakthrough in the Treatment of Patients with Multiple Myeloma

Excitement is growing for the treatment of patients with various forms of cancer using  immunotherapy — specific therapies that harness the power of a patient’s own immune system to combat their disease. The concept involves engineering chimeric antigen receptor T cells, also known as natural killer cells, for a specific antigen that is more prevalent in a specific disease...

Alectinib More Effective Compared to Current Standard of Care Crizotinib

Findings from a phase III clinical trial funded by funded by F. Hoffmann-La Roche, point to a more effective initial treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). In the open label clinical trial (ALEX; NCT02075840), researchers randomly assigned 303 patients with stage IIIB or IV, ALK-positive NSCLC to receive alectinib or crizotinib. The patients...

Dacomitinib may Offer New Treatment Option for Patients with EGFR-Positive Lung Cancer

Findings from a phase III clinical trial point to a potential new treatment for patients newly diagnosed with advanced, epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Compared to the EGFR inhibitor gefitinib (Iressa®; AstraZeneca), one of the standard targeted medicines for this disease, the investigational second-generation EGFR inhibitor dacomitinib (PF-00299804; Pfizer), delayed cancer growth by a...

Single-dose Radiation Therapy may help Relieve Debilitating Spinal Cord Compression

A common complication in people with metastatic cancer, spinal cord compression or SCC, is a major detriment to Quality of Life (QoL). The symptoms of spinal cord compression can vary. They may be mild at first or pain may be the only symptom. As the tumor puts more pressure on the spine, the symptoms become worse and more serious. Radiation...

Atezolizumab Shows Potential as Foundational Agent in the Treatment of Numerous Cancers

Data for atezolizumab (Tecentriq®; Genentech/Roche) were presented during the 53rd annual meeting of the American Society of Clinical Oncology (ASCO), held June 2 - 6, 2017 in Chicago, Illinois. The data from phase I, II and Phase III studies suggested that atezolizumab has the potential to be used as a foundational combination partner with cancer immunotherapies, targeted medicines and various...

Cancer Patients and Mental Health – a Focus at ASCO 2017

A diagnosis of advanced cancer weighs heavily on patients and families, and causes significant emotional distress. While doctors focus on addressing the health of a patient, mental health and emotional needs are often left to only the cancer patient and their families. At this year’s American Society of Clinical Oncology (ASCO) meeting, the importance of improving mental health and reducing...

Dramatic Progress in the Treatment of Childhood Cancers

Treatments for childhood cancer are often intense and carry an increased risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors, median age 28 years (range 5-63), in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after...

Clinical trial of Novel Immune-based Therapy may Benefit Patients with Advanced Pancreatic Tumors

While immune therapy has proven effective in treating certain types of cancer, especially lung cancer and melanoma, tumors of the pancreas remain among the most difficult to treat and, so far, are impervious to immune-based therapies. Now, for the first time, a new study in mice has shown that immunotherapy against pancreatic cancer can be effective when given in conjunction...

Fat Storage may make Cancer Cells more Aggressive

It has been established that not all cancer cells are equally aggressive – most can be neutralized with radiation and chemotherapy. Researchers at Lund University in Sweden have now discovered that some cancer cells can accumulate fat droplets, which appear to make them more aggressive and increase their ability to spread. The interior of a cancer tumor is a...

Positive Top Line Data Presented for Reolysin® in Randomized Phase III Study in Head and Neck Cancers

Initial positive top line data from the first endpoint in a double-blinded randomized Phase III clinical study examining Reolysin® (Reovirus Serotype 3 Dearing; Oncolytics), a proprietary formulation of the human reovirus, in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naïve head and neck cancers (REO 018; NCT01166542) were presented earlier today.The purpose of this phase III...

Related articles